Deutsch English Français

Contact

EP3094648

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3094648

EP3094648 - FC-REGION VARIANTS WITH IMPROVED PROTEIN A-BINDING [Right-click to bookmark this link]
Status	Examination is in progress Status updated on 20.11.2019 Database last updated on 18.10.2024
Former	Grant of patent is intended Status updated on 23.06.2019
Former	Examination is in progress Status updated on 20.10.2017
Most recent event Tooltip	09.10.2024	New entry: Decision (+date) in appeal procedure
Applicant(s)	For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH
	[N/P]
Former [2016/47]	For all designated states F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH
Inventor(s)	01 / SCHLOTHAUER, Tilman Sommerstrasse 3a 82377 Penzberg / DE
	[2016/47]
Representative(s)	Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
	[N/P]
Former [2016/47]	Burger, Alexander Roche Diagnostics GmbH Patent Department (LPP.....6164) P.O.Box 11 52 82372 Penzberg / DE
Application number, filing date	15700545.5	12.01.2015
	[2016/47]
	WO2015EP50389
Priority number, date	EP20140151322	15.01.2014 Original published format: EP 14151322
	EP20140165924	25.04.2014 Original published format: EP 14165924
	[2016/47]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015107015
	Date:	23.07.2015
	Language:	EN
	[2015/29]
	Type:	A1 Application with search report
	No.:	EP3094648
	Date:	23.11.2016
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 23.07.2015 takes the place of the publication of the European patent application.
	[2016/47]
Search report(s)	International search report - published on:	EP	23.07.2015
Classification	IPC:	A61K39/395, A61K9/00, A61K9/40, A61K45/06, C07K16/12	[2019/25]
	CPC:	C07K16/22 (EP,KR,RU,US); A61K9/0019 (RU,US); A61K39/395 (KR); A61K39/3955 (RU,US); A61K39/40 (RU,US); A61K45/06 (RU,US); (+) A61K9/0048 (RU,US); A61P27/02 (EP); A61P27/06 (EP); C07K16/1271 (RU,US); A61K2039/505 (EP,KR,US); C07K2317/31 (EP,KR,US); C07K2317/33 (EP,KR,US); C07K2317/524 (EP,KR,US); C07K2317/526 (EP,KR,US); C07K2317/53 (EP,KR,US); C07K2317/54 (US); C07K2317/64 (EP,KR,US); C07K2317/71 (EP,KR,US); C07K2317/92 (US); C07K2317/94 (EP,KR,US) (-)
	Former IPC [2016/47]	C07K16/22, A61K39/00
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/47]
Title	German:	FC-REGION-VARIANTEN MIT VERBESSERTER PROTEIN-A-BINDUNG	[2016/47]
	English:	FC-REGION VARIANTS WITH IMPROVED PROTEIN A-BINDING	[2016/47]
	French:	VARIANTS DE ZONE FC AVEC PROTÉINE DE LIGAND A AMÉLIORÉE	[2019/25]
	Former [2016/47]	VARIANTS DE RÉGION FC PRÉSENTANT UNE LIAISON AMÉLIORÉE À LA PROTÉINE A
Entry into regional phase	16.08.2016	National basic fee paid
	16.08.2016	Designation fee(s) paid
	16.08.2016	Examination fee paid
Examination procedure	deleted	Communication of intention to grant the patent
	16.06.2016	Amendment by applicant (claims and/or description)
	16.08.2016	Examination requested [2016/47]
	19.10.2017	Despatch of a communication from the examining division (Time limit: M06)
	20.04.2018	Reply to a communication from the examining division
	16.10.2018	Despatch of a communication from the examining division (Time limit: M02)
	20.12.2018	Reply to a communication from the examining division
	24.06.2019	Communication of intention to grant the patent
	22.10.2019	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	04.11.2019	Fee for grant paid
	04.11.2019	Fee for publishing/printing paid
	26.11.2019	Despatch of a communication from the examining division (Time limit: M04)
	16.12.2019	Reply to a communication from the examining division
	09.07.2020	Despatch of communication that the application is refused, reason: substantive examination {1}
	24.11.2023	Observations by third parties
	20.06.2024	Observations by third parties
	27.06.2024	Observations by third parties
	11.09.2024	Observations by third parties
Appeal following examination	07.09.2020	Appeal received No. T0056/21
	19.11.2020	Statement of grounds filed
	17.12.2021	Invitation to file observations in an appeal (Time limit: M02) [2021/51]
	15.02.2022	Date of receipt of observations in an appeal [2022/08]
	04.10.2024	Result of appeal procedure: remittal for grant
	14.10.2024	Despatch of the decision of the Board of Appeal
Divisional application(s)	EP20206487.9 / EP3842455
Fees paid	Renewal fee
	09.01.2017	Renewal fee patent year 03
	08.01.2018	Renewal fee patent year 04
	09.01.2019	Renewal fee patent year 05
	10.01.2020	Renewal fee patent year 06
	12.01.2021	Renewal fee patent year 07
	13.01.2022	Renewal fee patent year 08
	11.01.2023	Renewal fee patent year 09
	23.01.2024	Renewal fee patent year 10
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XI]US6277375 (WARD ELIZABETH SALLY [US]) [X] 1-3,5,18,19 * example 9 * * column 59, paragraphs 2-3 * * column 60, paragraph 3 * * column 12, paragraphs 4-5 * [I] 4;
		[XAI]US2008112961 (STAVENHAGEN JEFFREY B [US], et al) [X] 1-3,5,7,8,11,12,14,18,19 * claims 1-5 * * paragraphs [0042] , [0049] , [0 87] , [0 92] , [0197] , [0208] , [ 227] , [0266] * * tables 1,3-10 * [A] 9 [I] 4,6,10,13,15,17;
		[XA]US2010272720 (LO KIN-MING [US], et al) [X] 1-3,5-8,12,14,18,19 * paragraphs [0003] , [0 52] , [0053] , [0055] , [0060] , [0080] * * claims 1-10,33 * [A] 9,10,13,15-17;
		[XAI]WO2013004842 (GENMAB AS [DK], et al) [X] 1-8,11,12,14,18,19 * claims 1-29,40,42-43,56-57,68-78 * * table 1 * * page 38 - page 40 * * page 59, paragraph 3 - page 76, paragraph 6 * [A] 9,10 [I] 1;
		[I]AU2012233313 (CHUGAI PHARMACEUTICAL CO LTD) [I] 1-19 * page 88, paragraph 3 - page 89, paragraph 1 * * claims 1-5 * * page 98, paragraph last - page 99 * * example 12 *;
		[XA]WO2014006217 (GENMAB BV [NL]) [X] 1-5,7-9,11,12,14,18,19 * page 47, paragraphs 1-2 * * page 40, paragraph 4 - page 43, paragraph 7 * * claims 1-34,43-47 * * tables 13-12 * * page 87, paragraph 3 * [A] 10,17;
		[XA] - T. YING ET AL, "Soluble Monomeric IgG1 Fc", JOURNAL OF BIOLOGICAL CHEMISTRY, (20120601), vol. 287, no. 23, doi:10.1074/jbc.M112.368647, ISSN 0021-9258, pages 19399 - 19408, XP055063702 [X] 1-3,5,8,11,12,18,19 * the whole document * * figure 6 * * page 19401, column 1, paragraph 4 * * page 19403, column 2, paragraph 3 * [A] 7,9,10 DOI: http://dx.doi.org/10.1074/jbc.M112.368647
		[X] - MARTIN W L ET AL, "Crystal Structure at 2.8A of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, (20010401), vol. 7, doi:10.1016/S1097-2765(01)00230-1, ISSN 1097-2765, pages 867 - 877, XP003027710 [X] 1-3,5,12,18,19 * the whole document * * tables 3,4 * DOI: http://dx.doi.org/10.1016/S1097-2765(01)00230-1
		[XAI] - SHIELDS R L ET AL, "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20010302), vol. 276, no. 9, doi:10.1074/JBC.M009483200, ISSN 0021-9258, pages 6591 - 6604, XP002271092 [X] 1-3,5,7,12,18,19 * the whole document * * tables I,III * * page 6603, column 1, paragraph 2 * [A] 9,10,13-15 [I] 4 DOI: http://dx.doi.org/10.1074/jbc.M009483200
		[A] - KIM H ET AL, "FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye", vol. 15, ISSN 1090-0535, (20091216), pages 2803 - 2812, MOLECULAR VISION, MOLECULAR VISION, SN, ATLANTA, URL: http://www.molvis.org/molvis/v15/a296, (20141017), XP002688851 [A] 1-19 * the whole document *
		[A] - TIMOTHY T KUO ET AL, "Neonatal Fc Receptor: From Immunity to Therapeutics", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, (20101001), vol. 30, no. 6, doi:10.1007/S10875-010-9468-4, ISSN 1573-2592, pages 777 - 789, XP019858481 [A] 1-19 * the whole document * DOI: http://dx.doi.org/10.1007/s10875-010-9468-4
		[A] - KIM J-K ET AL, "Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, (19990901), vol. 29, no. 9, doi:10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6, ISSN 0014-2980, pages 2819 - 2825, XP002300286 [A] 1-19 * the whole document * DOI: http://dx.doi.org/10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6
	Examination	WO2014177461
		WO2014177460

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p